STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.

Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.

This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.

All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.

Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on November 5, 2020, at 8:00 a.m. CST to discuss its first quarter 2021 financial results. Investors can access the live call via phone or online. A replay will be available after the call until December 5, 2020. Bio-Techne, a leader in developing purified proteins and diagnostic products, reported approximately $739 million in net sales for fiscal 2020 and employs around 2,300 staff worldwide.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
conferences earnings
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) has opened a new office in Toronto, Canada, housing approximately 40 employees. This facility aims to support the Canadian life sciences industry and will service academic and biopharma clients with Bio-Techne's life science tools and diagnostic reagents. The Toronto office will also manufacture and distribute cartridges for the Protein Simple branded iCE and Maurice systems, enhancing the company’s production capacity. Designed for energy efficiency, it meets ISO 9001 standards to ensure high-quality operations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the grand opening of a 61,000 square foot GMP manufacturing facility in St. Paul, MN, investing $50 million. This facility aims to support large-scale production of GMP-grade materials essential for cell and gene therapies, particularly E. coli-derived recombinant proteins. With a growing demand driven by immuno-oncology and stem cell therapies, Bio-Techne is positioned to enhance its manufacturing capabilities and meet global market needs. Production is expected to begin in early 2021 after quality validation procedures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) announced a publication in BMC Urology regarding the ExoDx Prostate test (EPI). Conducted by Dr. James McKiernan and colleagues, the study found that EPI achieved a 92% negative predictive value for ruling out high-grade prostate cancer in men with prior negative biopsies, potentially avoiding 27% of unnecessary repeat biopsies. Prostate cancer remains a significant health concern, with over 3.6 million men living with it in the U.S. This study underscores the test's clinical benefits, elevating patient and physician confidence in biopsy decisions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the launch of its RNA-Protein Co-Detection Assays, enhancing the RNAscope™ technology. This innovation allows simultaneous examination of gene expression and secreted proteins in intact cells and tissues, addressing the challenges of traditional ISH and IHC methods. The assays utilize patented RNAscope and BaseScope™ technologies for improved specificity and sensitivity. Bio-Techne aims to combine its extensive antibody portfolio with RNAscope technology, facilitating advanced research in infectious diseases and cancer biology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.33%
Tags
none
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its B-MoGen Biotechnologies portfolio to R&D Systems on September 21, 2020. This change includes the retirement of the B-MoGen website, with all products and services now accessible through R&D Systems' site. President Dave Eansor highlighted that this consolidation aims to enhance service offerings for cell and gene therapy customers, providing value-added services alongside high-quality products. More details on the TcBuster gene transfer system can be found on their new site.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
none
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) and QIAGEN N.V. have expanded their non-exclusive partnership focusing on exosome technology. The agreement allows QIAGEN to use Bio-Techne's exosome technology for developing companion in vitro diagnostic products. This partnership will promote the technology among biopharma partners for an initial 24 months, potentially extendable. Furthermore, both companies are extending their exclusive collaboration for product development through Exosome Diagnostics until 2028, enhancing marketing efforts around exosome technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.26%
Tags
partnership
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) has partnered with baseball legend Cal Ripken Jr. to promote prostate cancer awareness, coinciding with Prostate Cancer Awareness Month. Ripken, who was treated for prostate cancer, aims to educate men about the ExoDx™ Prostate test, pivotal in his own health journey. The test assists in biopsy decisions and has gained Medicare coverage, as well as recognition from the VA Healthcare system and NCCN guidelines. Bio-Techne's EPI test is now available with an at-home collection kit, enhancing accessibility for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
partnership
-
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ: TECH) will be presenting at the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020, at 11:20 a.m. EDT. The presentation will be led by Chuck Kummeth, the company's CEO. Interested parties can access the live webcast via Bio-Techne's Investor Relations website. In fiscal 2020, Bio-Techne generated approximately $739 million in net sales and is known for its high-quality proteins and diagnostic products used in biological research and clinical diagnostics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
Rhea-AI Summary

Bio-Techne Corporation (NASDAQ:TECH) partnered with Leica Biosystems to automate RNAscope™ COVID-19 probes on the BOND RX* platform for research use. This advancement enables researchers to enhance their COVID-19 research protocols, minimizing manual labor and turnaround time. RNAscope™ probes detect SARS-Cov-2 RNA and related sequences, facilitating quicker breakthroughs in vaccine and treatment research. Bio-Techne generated approximately $739 million in net sales in fiscal 2020 and holds a diverse portfolio in diagnostic and genomic products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
covid-19
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

7.60B
156.43M
1.05%
101.12%
3.33%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
MINNEAPOLIS